The payment codes, effective Feb. 11, are for bebtelovimab. The drug was authorized last week by the FDA to treat patients who are at high risk for progression to severe COVID-19 or hospitalization.
There are several new codes:
- Q0222: injection, bebtelovimab, 175 mg
- M0222: intravenous injection, bebtelovimab, including injection and post-administration monitoring
- M0223: intravenous injection, bebtelovimab, including injection and post-administration monitoring in the home or residence
